Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
China Infrastructure Construction Corp. (CHNC) operates primarily in the healthcare sector, focusing on drug manufacturing, particularly in specialty and generic pharmaceuticals. The company's competitive position is bolstered by its high gross margin of 86.8%, although it currently faces significant operational challenges reflected in its negative operating and net margins.
CHNC generates revenue through the production and sale of specialty and generic drugs, leveraging its high gross margins to maintain pricing power in a competitive market. The company's focus on high-demand therapeutic areas provides a competitive advantage, although its operational inefficiencies currently hinder profitability.
Changes in regulatory approvals for new drugs
Market demand for specialty pharmaceuticals
Pricing pressures in the generic drug market
Operational efficiency improvements
Regulatory changes affecting drug approvals and pricing
Technological disruption in drug manufacturing processes
Intense competition from both established pharmaceutical companies and new entrants in the generic market
Potential for price wars in the generic drug segment
Negative operating cash flow impacting liquidity
High reliance on equity financing due to negative debt levels
moderate - The healthcare sector is somewhat insulated from economic downturns, but demand for pharmaceuticals can be affected by overall consumer spending.
Interest rates impact CHNC's financing costs for R&D and production expansion, affecting its valuation multiples as higher rates may lead to increased costs of capital.
minimal - The company has a negative debt-to-equity ratio, indicating limited reliance on external financing.
growth - Investors may be attracted to potential turnaround opportunities given the company's revenue growth despite current operational challenges.
high - The company's stock has experienced significant volatility, as indicated by its -64.3% return over the past year.